Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.48 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.40 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.36 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL435512 | 1.00 | AKR1C1 (0.48) | AKR1C1HDAC4HSD11B1LMNAHTT | |
| SCHEMBL10659448 | 1.00 | AKR1C1 (0.48) | AKR1C1HDAC4HSD11B1LMNAHTT | |
| Hydrochloric Acid SCHEMBL8114401 | 0.98 | AKR1C1 (0.47) | AKR1C1HDAC4HSD11B1LMNAHTT | |
| Hydrochloric Acid SCHEMBL8114403 | 0.98 | AKR1C1 (0.47) | AKR1C1HDAC4HSD11B1LMNAHTT | |
| SCHEMBL16057460 | 0.95 | AKR1C1 (0.52) | AKR1C1HDAC4HSD11B1LMNAHTT | |
| SCHEMBL11241224 | 0.90 | AKR1C1 (0.40) | AKR1C1ALDH1A1 | |
| Hydrochloric Acid SCHEMBL11247968 | 0.89 | AKR1C1 (0.39) | AKR1C1 | |
| SCHEMBL11241214 | 0.86 | MMP2 (0.40) | AKR1C1 | |
| SCHEMBL11231091 | 0.86 | PLA2G10 (0.39) | AKR1C1HSD11B1LMNA | |
| SCHEMBL11234892 | 0.86 | ALDH1A1 (0.39) | AKR1C1HDAC4ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 367 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118271224-A | Preparation method of (2S, 4S) -4-cyclohexyl-L-proline | 浙江华海药业股份有限公司 | 2024-07-02 | — | — | CN | claimed |
| CN-114516825-A | Method for preparing (2S,4S) -4-cyclohexyl-L-proline | 浙江华海药业股份有限公司 | 2022-05-20 | — | — | CN | claimed |
| CN-111303002-B | Method for treating fosinopril intermediate mother liquor | 浙江工业大学 | 2021-05-07 | — | — | CN | claimed |
| CN-111303002-A | Method for treating fosinopril intermediate mother liquor | 浙江工业大学 | 2020-06-19 | — | — | CN | claimed |
| US-8980843-B2 | Leptin agonist and methods of use | Temple University—Of the Commonwealth System of Higher Education (US) | 2015-03-17 | — | — | US | claimed |
| WO-1993000359-A1 | MODIFIED PEPTIDES TRANSPORTABLE INTO THE CENTRAL NERVOUS SYSTEM | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1993-01-07 | — | — | WO | claimed |
| US-4912231-A | Reacting a proline derivative with an aromatic nucleophile in presence of a Lewis acid catalyst | E. R. SQUIBB & SONS, INC. (US) | 1990-03-27 | — | — | US | claimed |
| JP-1016761-A | — | — | None | — | — | JP | disclosed |
| US-12421279-B2 | Cyclic peptide antiviral agents and methods using same | DREXEL UNIVERSITY (US) | 2025-09-23 | — | — | US | disclosed |
| US-20250099533-A1 | ADIPONECTIN PEPTIDOMIMETICS FORMULATIONS | ALLYSTA PHARMACEUTICALS INC (US) | 2025-03-27 | — | — | US | disclosed |
| US-20250059235-A1 | CYCLIC PEPTIDE ANTIVIRAL AGENTS AND METHODS USING SAME | UNIV DREXEL (US) | 2025-02-20 | — | — | US | disclosed |
| US-12201668-B2 | Adiponectin peptidomimetics formulations | ALLYSTA PHARMACEUTICALS, INC. (US) | 2025-01-21 | — | — | US | disclosed |
| CN-114042171-B | Bacterial imaging agents and methods of use thereof | 文森医学公司 | 2024-12-06 | — | — | CN | disclosed |
| US-4470973-A | HYPOTENSIVE AGENTS, ANALGESICS | E. R. SQUIBB & SONS, INC. (US) | 1984-09-11 | — | — | US | disclosed |
| US-4462943-A | HYPOTENSIVE AGENTS | E. R. SQUIBB & SONS, INC. (US) | 1984-07-31 | — | — | US | disclosed |
| US-4384123-A | Phosphinylalkanoyl substituted prolines | E. R. SQUIBB & SONS, INC. (US) | 1983-05-17 | — | — | US | disclosed |
| US-4337201-A | Phosphinylalkanoyl substituted prolines | E. R. SQUIBB & SONS, INC. (US) | 1982-06-29 | — | — | US | disclosed |
| EP-0053902-A1 | Phosphinylalkanoyl substituted prolines | E.R. Squibb & Sons, Inc. (US) | 1982-06-16 | — | — | EP | disclosed |
| EP-0052991-A1 | Carboxyalkyl amino acid derivatives of various substituted prolines | E.R. Squibb & Sons, Inc. (US) | 1982-06-02 | — | — | EP | disclosed |
| US-4316905-A | HYPOTENSIVE AGENTS | E. R. SQUIBB & SONS, INC. (US) | 1982-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250059235-A1 | CYCLIC PEPTIDE ANTIVIRAL AGENTS AND METHODS USING SAME | ZC3HAV1, VIP, LNPEP | AKR1C1 4452/4885HDAC4 2966/4885HSD11B1 4217/4885 |
| US-12421279-B2 | Cyclic peptide antiviral agents and methods using same | ZC3HAV1, VIP, LNPEP | AKR1C1 4452/4885HDAC4 2966/4885HSD11B1 4217/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.